RESUMO
Despite success in achieving viral suppression during pregnancy in people living with HIV (PLWH), postpartum adherence remains a challenge. We aimed to describe rates of adherence at a Prevention of Mother-to-Child HIV Transmission (PMTCT) Center before and during the COVID-19 pandemic. This study was conducted from a cohort of PLWH who received prenatal care and were virally suppressed near delivery. We tracked combined antiretroviral therapy (cART) pickups for 12 months and HIV viral load (VL) from 2 to 12 months after delivery. We defined flexible adherence as a monthly pickup of cART and strict adherence as also having VL < 200 copies/mL and at least one maternal HIV VL between two and twelve months postpartum. Pre-pandemic was defined as delivery from March 2017-February 2019 and pandemic as March 2020-February 2022. During the study, 1119 PLWH were followed, and 965 (86%) were suppressed near delivery. There were 511 pre-pandemic and 290 pandemic participants. Adherence rates were 66/511 (13%) and 38/290 (13%), respectively. During the pandemic, more participants conceived using cART and were undetectable at the start of prenatal care; nevertheless, postpartum adherence was no better than pre-pandemic underscoring the need to improve strategies for adherence specific to this subset of PLWH in the postpartum period.
RESUMO
OBJECTIVES: To update nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) resistance rates and describe the frequency of HIV subtypes in a cohort of pregnant people living with HIV (PPLH) at a national Prevention of Mother-To-Child HIV Transmission (PMTCT) centre. METHODS: We evaluated genotypic resistance among PPLH during prenatal care who were antiretroviral therapy-naïve or experienced. We determined mutations by the Surveillance of Drug Resistance Mutations (SDRM) dataset and also focused on studying participants with intermediate or high resistance defined through the Stanford score. RESULTS: From 2018 to 2021, 1170 PPLH received prenatal care at the centre and 550 were genotyped. Among the 295 SDRMs, with respect to NRTI resistance mutations, there were 27/295 (9.2%) M184V/I, 14/295 (4.7%) T215Y/C/D/E/F/V/I/S and 12/295 (4.1%) M41L. For NNRTI, there were 75/295 (25.4%) K103N, 18/295 (6.1%) M230L and 14/295 (4.7%) G190A/E/S mutations. For PI, the most frequent mutations were 13/295 (4.4%) V82A/S/F/T, 12/295 (4.1%) M46I/L and 10/295 (3.4%) D30N. Based on the Stanford score, 36/224 (16%) naïve participants had one or more antiretroviral resistance mutations, 81% of whom had NNRTI resistance. In the treatment-experience group, 108/326 (33%) had one or more mutations, 91% of whom had NNRTI resistance. The most frequent HIV subtype was B (82.5%). CONCLUSIONS: Our findings suggest that continuous surveys of HIV genotype appear to be important tools to map the distribution and evolution of HIV subtypes and resistance to provide information to support treatment policies. Furthermore, concerns about the use of rilpivirine-containing regimens underscore the importance of resistance surveillance.
Assuntos
Fármacos Anti-HIV , Infecções por HIV , HIV-1 , Humanos , Feminino , Gravidez , Fármacos Anti-HIV/farmacologia , Fármacos Anti-HIV/uso terapêutico , Inibidores da Transcriptase Reversa/uso terapêutico , Inibidores da Transcriptase Reversa/farmacologia , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , HIV-1/genética , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Antirretrovirais/uso terapêutico , Mutação , Genótipo , Farmacorresistência Viral/genéticaRESUMO
INTRODUCTION: Acute febrile illnesses (AFI) are a frequent chief complaint in outpatients. Because the capacity to investigate the causative pathogen of AFIs is limited in low- and middle-income countries, patient management may be suboptimal. Understanding the distribution of causes of AFI can improve patient outcomes. This study aims to describe the most common etiologies diagnosed over a 16-years period in a national reference center for tropical diseases in a large urban center in Rio de Janeiro, Brazil. METHODS: From August 2004-December 2019, 3591 patients > 12 years old, with AFI and/or rash were eligible. Complementary exams for etiological investigation were requested using syndromic classification as a decision guide. Results. Among the 3591 patients included, endemic arboviruses such as chikungunya (21%), dengue (15%) and zika (6%) were the most common laboratory-confirmed diagnosis, together with travel-related malaria (11%). Clinical presumptive diagnosis lacked sensitivity for emerging diseases such as zika (31%). Rickettsia disease and leptospirosis were rarely investigated and an infrequent finding when based purely on clinical features. Respiratory symptoms increased the odds for the diagnostic remaining inconclusive. CONCLUSIONS: Numerous patients did not have a conclusive etiologic diagnosis. Since syndromic classification used for standardization of etiological investigation and presumptive clinical diagnosis had moderate accuracy, it is necessary to incorporate new diagnostic technologies to improve diagnostic accuracy and surveillance capacity.
Assuntos
Doenças Transmissíveis , Dengue , Infecção por Zika virus , Zika virus , Humanos , Criança , Vigilância de Evento Sentinela , Viagem , Brasil/epidemiologia , Doença Relacionada a Viagens , Infecção por Zika virus/diagnóstico , Infecção por Zika virus/epidemiologia , Dengue/diagnóstico , Dengue/epidemiologiaRESUMO
OBJECTIVES: We assessed real-world weight change and pregnancy outcomes among pregnant women living with HIV who used integrase strand transferase inhibitor (INSTI)-based combined antiretroviral therapy (cART). METHODS: In a retrospective cohort study from 2014 to 2021 for prevention of perinatal HIV infection, we evaluated changes in weight from the first prenatal visit to near delivery for two groups. The categories of change were: low (< 0.18 kg/week), normal (0.18-0.59 kg/week), and high (> 0.59 kg/week). The backbones were lamivudine + tenofovir disoproxil or lamivudine + zidovudine. The comparison groups were women with body mass index (BMI) < 25 kg/m2 versus BMI ≥ 25 kg/m2 and INSTI-naïve versus INSTI-experienced. Continuous variables were analysed with a Kruskal-Wallis test and count or categorical data with χ2 tests. RESULTS: We enrolled 198 pregnant women. At study entry, 74 had BMI < 25 kg/m2 and 124 had BMI ≥ 25 kg/m2 . Excess gestational weight gain was more frequent among women who were INSTI-naïve among both BMI groups (< 25 and ≥ 25). However, the proportion of participants per weight change category was only significantly different between INSTI-naïve women with baseline BMI < 25 kg/m2 and INSTI-experienced women with BMI < 25 kg/m2 . In particular, INSTI-naïve women with BMI < 25 kg/m2 had significantly higher rates of excess gestational weight gain (31.6%) compared with participants with BMI < 25 kg/m2 who conceived while on INSTIs (11.8%, p = 0.004). Rates of unfavourable pregnancy outcomes were low and did not differ significantly between groups. CONCLUSIONS: INSTI-naïve participants with BMI < 25 kg/m2 gained more weight during pregnancy than participants with BMI ≥ 25 kg/m2 who conceived while using INSTIs. Rates of adverse pregnancy outcomes did not differ between the groups.
Assuntos
Fármacos Anti-HIV , Ganho de Peso na Gestação , Infecções por HIV , Inibidores de Integrase de HIV , Integrase de HIV , Humanos , Feminino , Gravidez , Masculino , Infecções por HIV/tratamento farmacológico , Lamivudina/uso terapêutico , Gestantes , Estudos Retrospectivos , Fármacos Anti-HIV/uso terapêutico , Aumento de Peso , Inibidores de Integrase de HIV/uso terapêutico , Resultado da GravidezRESUMO
There are some reports and case series addressing Coronavirus Disease 2019 (COVID-19) infections during pregnancy in upper income countries, but there are few data on pregnant women with comorbid conditions in low and middle income Countries. This study evaluated the proportion and the maternal and neonatal outcomes associated with SARS-CoV-2 infection among pregnant women with comorbidities. Participants were recruited consecutively in order of admission to a maternity for pregnant women with comorbidities. Sociodemographic, clinical, and laboratory data were prospectively collected during hospitalization. Pregnant women were screened at entry: nasopharyngeal swabs were tested by RT-PCR; serum samples were tested for IgG antibodies against spike protein by ELISA. From April to June 2020, 115 eligible women were included in the study. The proportion of SARS-CoV-2 infection was 28.7%. The rate of obesity was 60.9%, vascular hypertension 40.0%, and HIV 21.7%. The most common clinical presentations were ageusia (21.2%), anosmia (18.2%), and fever (18.2%). Prematurity was higher among mothers who had a SARS-CoV-2 infection based on RT-PCR. There were two cases of fetal demise. We found a high proportion of COVID-19 among pregnant women with comorbidities. This underscores the importance of antenatal care during the pandemic to implement universal SARS-CoV-2 screening, precautionary measures, and the rollout of vaccination programs for pregnant women.
Assuntos
COVID-19/epidemiologia , Imunoglobulina G/sangue , Complicações Infecciosas na Gravidez/epidemiologia , Complicações Infecciosas na Gravidez/virologia , SARS-CoV-2/imunologia , Adulto , COVID-19/imunologia , Estudos de Coortes , Comorbidade , Feminino , Hospitalização , Humanos , Recém-Nascido , Transmissão Vertical de Doenças Infecciosas , Obesidade/complicações , Obesidade/virologia , Projetos Piloto , Gravidez , Gestantes , SARS-CoV-2/genética , Adulto JovemRESUMO
Tuberculosis is the leading cause of death amongst adults with human immunodeficiency virus (HIV) infection. The lifetime risk of tuberculosis disease for a person with latent infection is estimated at 5-10% with most cases occurring within five years of initial infection. The World Health Organization recommends isoniazid preventive therapy (IPT) for latent tuberculosis treatment, amongst other strategies. The aim was to assess tuberculosis incidence, survival (free of tuberculosis) and associated factors in HIV-positive patients. IPT was offered to participants with a positive (≥5mm) tuberculin skin test. Participants were followed from February 2003-December 2016. Kaplan-Meier was used for survival analysis. Variables with p-value ≤ 0.2 in the univariate analysis entered into the multivariate Cox-Model, keeping those with p-value ≤ 0.05. The 95% confidence interval of incidence of tuberculosis was estimated using Poisson distribution. One hundred nineteen patients completed the IPT and were followed for a median duration of 110.7 months (IQR 93.1-121.0). The probability of developing tuberculosis (10 years post-IPT) was 5.4%. Tuberculosis incidence was 0.58/100 patient/years (CI 95% 0.213-1.264). IPT over 6 months provided long-term protection against tuberculosis. AIDS-defining illness was the only statistically significant variable (HR=5.67) in the multivariate model.
Assuntos
Humanos , Análise de Sobrevida , HIV , Tuberculose Latente , IsoniazidaRESUMO
Few studies have compared the clinical efficacy and adverse events of combined antiretroviral therapy (cART) regimens in pregnant women seeking obstetrical care. The objective of this study was to compare the efficacy (virus load response), adverse events, and obstetrical and neonatal outcomes of three different regimens of cART in HIV-infected pregnant women initiating treatment in Rio de Janeiro, Brazil. This was a retrospective cohort study of cART-naive pregnant women who initiated either ritonavir-boosted protease inhibitors (atazanavir or lopinavir), efavirenz, or raltegravir plus a backbone regimen. From 2014 to 2018, 390 pregnant women were followed over time. At baseline, the median viral load (VL) for HIV was 4.1 log copies/ml. Among participants who received cART for 2 to 7 weeks, the VL decline was greater for raltegravir (2.24 log copies/ml) than for efavirenz or protease inhibitors (P < 0.001). Virologic suppression was achieved in 87% of women on raltegravir near delivery versus 73% on efavirenz and 70% on protease inhibitors (P = 0.011). Patients on raltegravir achieved virologic suppression faster than those on other regimens (P = 0.019). Overall, the HIV perinatal infection rate was 1.5%. This clinical study compared three potent and well-tolerated cART regimens and demonstrated that a higher proportion of participants on raltegravir achieved an undetectable HIV VL near delivery (P = 0.011) compared to the other arms. These findings suggest that raltegravir-containing regimens are optimal regimens for women with HIV initiating treatment late in pregnancy.
Assuntos
Fármacos Anti-HIV , Infecções por HIV , HIV-1 , Complicações Infecciosas na Gravidez , Fármacos Anti-HIV/uso terapêutico , Brasil , Feminino , Infecções por HIV/tratamento farmacológico , Humanos , Lactente , Recém-Nascido , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Estudos Retrospectivos , Inibidores da Transcriptase Reversa/uso terapêutico , Resultado do Tratamento , Carga ViralRESUMO
This paper focuses on our research and intervention in health promotion with patients and communities affected by various infectious diseases, in the project Knowledge-Sharing Platform. This project is developed at the National Institute of Infectious Diseases Evandro Chagas in the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, and promotes the continuing involvement of health researchers and professionals in the collaborative production of knowledge on health with patients and community groups and in their training as community health promoters. The new epidemic scenario created the demand for a space of dialogue and knowledge-sharing on the prevention of COVID-19 transmission. Due to the interruption of regular activities in the Knowledge-Sharing Platform, a strategy was launched to serve as a link between science and society and help overcome the social isolation imposed by the COVID-19 pandemic. The WhatsApp group allowed project members to participate by addressing questions (audio) on COVID-19 through mediation by community group leaders. The main questions by participants related to risk factors, transmission, immunity to the novel coronavirus, care related to prevention, symptoms, and treatment; and COVID-19 and influenza vaccine. The educational material Caring in the Age of COVID-19 was produced and shared with community leaders and distributed to the respective groups and was eventually shared in their communities as a response to a demand for knowledge that responds to the concerns of people already exposed to structural vulnerability.
Esta comunicação é centrada na nossa pesquisa e intervenção em promoção da saúde com pacientes e comunidades afetadas por diversas doenças infecciosas, no projeto Plataforma de Saberes. Esse projeto é desenvolvido no Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, no Rio de Janeiro, Brasil, e promove o envolvimento continuado de pesquisadores e profissionais de saúde na produção colaborativa de conhecimento sobre saúde com pacientes e grupos comunitários, e na sua capacitação como promotores de saúde comunitária. Face ao novo cenário epidêmico, surgiu a demanda de um espaço de diálogo e partilha de conhecimento sobre prevenção da transmissão da COVID-19. Devido à interrupção das atividades regulares do Plataforma de Saberes, foi promovida uma estratégia que servisse de elo integrador entre ciência e sociedade e ajudasse a superar o isolamento social imposto pela pandemia da COVID-19. O grupo de WhatsApp possibilitou aos integrantes do projeto participarem por meio de formulação de perguntas (áudio) sobre a COVID-19, por intermédio da mediação dos líderes de grupos comunitários. Os principais questionamentos dos participantes estão relacionados com fatores de risco; formas de transmissão; imunidade ao novo vírus; cuidados relacionados à prevenção, sintomas e tratamento; COVID-19 e vacina da influenza. O material educativo Cuidar em tempos da COVID-19 foi produzido e compartilhado com os líderes comunitários e disponibilizado aos respectivos grupos, e veio a ser disseminado nas suas comunidades como resposta a uma demanda de conhecimento que responde às preocupações vividas pelos que já se encontram em situação de vulnerabilidade estrutural.
Esta comunicación se centra en nuestra investigación e intervención en la promoción de la salud con pacientes y comunidades afectadas por diversas enfermedades infecciosas, en el proyecto Plataforma de Saberes. Este proyecto está desarrollado en el Instituto Nacional de Infectología Evandro Chagas/Fundación Oswaldo Cruz, en Río de Janeiro, Brasil, y promueve la implicación continuada de investigadores y profesionales de salud en la producción colaborativa de conocimiento sobre salud con pacientes y grupos comunitarios, y en su capacitación como promotores de salud comunitaria. Frente al nuevo escenario epidémico, surgió la demanda de un espacio de diálogo e intercambio de conocimiento sobre la prevención de la transmisión de la COVID-19. Debido a la interrupción de las actividades regulares de la Plataforma de Saberes, se promovió una estrategia que sirviese de vínculo integrador entre ciencia y sociedad y ayudase a superar el aislamiento social impuesto por la pandemia de la COVID-19. El grupo de WhatsApp posibilitó a los integrantes del proyecto, que participaran mediante la formulación de preguntas (audio) sobre la COVID-19, a través de la mediación de los líderes de grupos comunitarios. Los principales cuestionamientos de los participantes se relacionaron con factores de riesgo; formas de transmisión; inmunidad ante el nuevo virus; cuidados relacionados con la prevención, síntomas y tratamiento; COVID-19 y vacuna de la gripe. El material educativo Cuidar em tempos da COVID-19 se produjo y se compartió con los líderes comunitarios y fue puesto a disposición de los respectivos grupos, así como difundido en sus comunidades, en respuesta a una demanda de conocimiento que responde a las preocupaciones vividas por los que ya se encuentran en situación de vulnerabilidad estructural.
Assuntos
Betacoronavirus , Infecções por Coronavirus/prevenção & controle , Promoção da Saúde/métodos , Disseminação de Informação/métodos , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Mídias Sociais , Populações Vulneráveis , Acesso à Informação , Brasil/epidemiologia , COVID-19 , Participação da Comunidade/métodos , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/transmissão , Humanos , Pneumonia Viral/epidemiologia , Pneumonia Viral/transmissão , SARS-CoV-2 , Isolamento SocialRESUMO
Despite the investment in prevention of mother-to-child transmission of HIV, there is still little data about the proportion of women that are retained in treatment after pregnancy in Brazil. Research worldwide shows that a significant proportion of women drop out of treatment after pregnancy. The aim of this study was to identify factors associated with treatment dropout of women that received prenatal care at a federal hospital in Rio de Janeiro between 2016 and 2017 and abandoned treatment after pregnancy. This was a retrospective cohort study using data on prescription refills and hospital medical records. Cross-sectional analysis of data from 454 women showed that 18% were not on cART after pregnancy. Illicit drug use during pregnancy, being less than 35 years old, and being aware of HIV diagnosis before conceiving but not taking cART were factors associated with treatment interruption postpartum. The high prevalence of interruption of HIV treatment after pregnancy suggests that there is a need for better post-natal care to increase adherence in this population.
Assuntos
Infecções por HIV , Pacientes Desistentes do Tratamento , Complicações Infecciosas na Gravidez , Adulto , Brasil/epidemiologia , Criança , Estudos Transversais , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Infecções por HIV/transmissão , Humanos , Transmissão Vertical de Doenças Infecciosas , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Complicações Infecciosas na Gravidez/epidemiologia , Estudos RetrospectivosRESUMO
Resumo: Esta comunicação é centrada na nossa pesquisa e intervenção em promoção da saúde com pacientes e comunidades afetadas por diversas doenças infecciosas, no projeto Plataforma de Saberes. Esse projeto é desenvolvido no Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, no Rio de Janeiro, Brasil, e promove o envolvimento continuado de pesquisadores e profissionais de saúde na produção colaborativa de conhecimento sobre saúde com pacientes e grupos comunitários, e na sua capacitação como promotores de saúde comunitária. Face ao novo cenário epidêmico, surgiu a demanda de um espaço de diálogo e partilha de conhecimento sobre prevenção da transmissão da COVID-19. Devido à interrupção das atividades regulares do Plataforma de Saberes, foi promovida uma estratégia que servisse de elo integrador entre ciência e sociedade e ajudasse a superar o isolamento social imposto pela pandemia da COVID-19. O grupo de WhatsApp possibilitou aos integrantes do projeto participarem por meio de formulação de perguntas (áudio) sobre a COVID-19, por intermédio da mediação dos líderes de grupos comunitários. Os principais questionamentos dos participantes estão relacionados com fatores de risco; formas de transmissão; imunidade ao novo vírus; cuidados relacionados à prevenção, sintomas e tratamento; COVID-19 e vacina da influenza. O material educativo Cuidar em tempos da COVID-19 foi produzido e compartilhado com os líderes comunitários e disponibilizado aos respectivos grupos, e veio a ser disseminado nas suas comunidades como resposta a uma demanda de conhecimento que responde às preocupações vividas pelos que já se encontram em situação de vulnerabilidade estrutural.
Resumen: Esta comunicación se centra en nuestra investigación e intervención en la promoción de la salud con pacientes y comunidades afectadas por diversas enfermedades infecciosas, en el proyecto Plataforma de Saberes. Este proyecto está desarrollado en el Instituto Nacional de Infectología Evandro Chagas/Fundación Oswaldo Cruz, en Río de Janeiro, Brasil, y promueve la implicación continuada de investigadores y profesionales de salud en la producción colaborativa de conocimiento sobre salud con pacientes y grupos comunitarios, y en su capacitación como promotores de salud comunitaria. Frente al nuevo escenario epidémico, surgió la demanda de un espacio de diálogo e intercambio de conocimiento sobre la prevención de la transmisión de la COVID-19. Debido a la interrupción de las actividades regulares de la Plataforma de Saberes, se promovió una estrategia que sirviese de vínculo integrador entre ciencia y sociedad y ayudase a superar el aislamiento social impuesto por la pandemia de la COVID-19. El grupo de WhatsApp posibilitó a los integrantes del proyecto, que participaran mediante la formulación de preguntas (audio) sobre la COVID-19, a través de la mediación de los líderes de grupos comunitarios. Los principales cuestionamientos de los participantes se relacionaron con factores de riesgo; formas de transmisión; inmunidad ante el nuevo virus; cuidados relacionados con la prevención, síntomas y tratamiento; COVID-19 y vacuna de la gripe. El material educativo Cuidar em tempos da COVID-19 se produjo y se compartió con los líderes comunitarios y fue puesto a disposición de los respectivos grupos, así como difundido en sus comunidades, en respuesta a una demanda de conocimiento que responde a las preocupaciones vividas por los que ya se encuentran en situación de vulnerabilidad estructural.
Abstract: This paper focuses on our research and intervention in health promotion with patients and communities affected by various infectious diseases, in the project Knowledge-Sharing Platform. This project is developed at the National Institute of Infectious Diseases Evandro Chagas in the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, and promotes the continuing involvement of health researchers and professionals in the collaborative production of knowledge on health with patients and community groups and in their training as community health promoters. The new epidemic scenario created the demand for a space of dialogue and knowledge-sharing on the prevention of COVID-19 transmission. Due to the interruption of regular activities in the Knowledge-Sharing Platform, a strategy was launched to serve as a link between science and society and help overcome the social isolation imposed by the COVID-19 pandemic. The WhatsApp group allowed project members to participate by addressing questions (audio) on COVID-19 through mediation by community group leaders. The main questions by participants related to risk factors, transmission, immunity to the novel coronavirus, care related to prevention, symptoms, and treatment; and COVID-19 and influenza vaccine. The educational material Caring in the Age of COVID-19 was produced and shared with community leaders and distributed to the respective groups and was eventually shared in their communities as a response to a demand for knowledge that responds to the concerns of people already exposed to structural vulnerability.
Assuntos
Humanos , Pneumonia Viral/prevenção & controle , Infecções por Coronavirus/prevenção & controle , Disseminação de Informação/métodos , Populações Vulneráveis , Pandemias/prevenção & controle , Mídias Sociais , Betacoronavirus , Promoção da Saúde/métodos , Pneumonia Viral/transmissão , Pneumonia Viral/epidemiologia , Isolamento Social , Brasil/epidemiologia , Infecções por Coronavirus/transmissão , Infecções por Coronavirus/epidemiologia , Participação da Comunidade/métodos , Acesso à Informação , SARS-CoV-2 , COVID-19RESUMO
BACKGROUND: Zika virus (ZIKV) was first isolated in Uganda in 1947. In Brazil, the first reported case of ZIKV infection was in May 2015. Additionally, dengue (DENV) is endemic and there has been a recent outbreak of chikungunya (CHIKV). Since the clinical manifestations of different arboviral infections (AI) can be similar, definitive diagnosis requires laboratory testing. OBJECTIVES: To determine the prevalence of ZIKV, DENV, and CHIKV infections in a Brazilian cohort of HIV-infected pregnant women, to assess clinical/immunological characteristics and pregnancy outcomes of women with evidence of recent AI. STUDY DESIGN: Laboratory diagnosis of ZIKV, DENV and CHIKV infections utilized serological assays, RT-PCR and PRNT. The tests were performed at the first visit, 34-36 weeks of gestation and at any time if a woman had symptoms suggestive of AI. Mann-Whitney tests were used for comparison of medians, Chi-square or Fisher's to compare proportions; p< 0.05 was considered statistically significant. Poisson regression was used to analyze risk factors for central nervous system (CNS) malformations in the infant according to maternal symptomatology. RESULTS: Of 219 HIV-infected pregnant women enrolled, 92% were DENV IgG+; 47(22%) had laboratory evidence of recent AI. Of these, 34 (72%) were ZIKV+, nine (19%) CHIKV+, and two (4%) DENV+. Symptoms consistent with AI were observed in 23 (10%) women, of whom 10 (43%) were ZIKV+, eight (35%) CHIKV+. No CNS abnormalities were observed among infants of DENV+ or CHIKV+ women; four infants with CNS abnormalities were born to ZIKV+ women (three symptomatic). Infants born to ZIKV+ women had a higher risk of CNS malformations if the mother was symptomatic (RR = 7.20), albeit not statistically significant (p = 0.066). CONCLUSIONS: Among HIV-infected pregnant women with laboratory evidence of a recent AI, 72% were ZIKV-infected. In this cohort, CNS malformations occurred among infants born to both symptomatic and asymptomatic pregnant women with Zika infection.
Assuntos
Coinfecção/epidemiologia , Anormalidades Congênitas/epidemiologia , Anormalidades Congênitas/etiologia , Infecções por HIV/complicações , Infecções por HIV/epidemiologia , Complicações Infecciosas na Gravidez/epidemiologia , Infecção por Zika virus/complicações , Infecção por Zika virus/epidemiologia , Adulto , Algoritmos , Brasil/epidemiologia , Sistema Nervoso Central/anormalidades , Febre de Chikungunya/complicações , Febre de Chikungunya/diagnóstico , Febre de Chikungunya/epidemiologia , Estudos de Coortes , Coinfecção/diagnóstico , Dengue/complicações , Dengue/diagnóstico , Dengue/epidemiologia , Surtos de Doenças , Feminino , Humanos , Recém-Nascido , Masculino , Gravidez , Complicações Infecciosas na Gravidez/diagnóstico , Resultado da Gravidez , Prevalência , Fatores de Risco , Adulto Jovem , Infecção por Zika virus/diagnósticoRESUMO
We describe a case of Zika virus infection acquired during the first trimester in a HIV-infected pregnant woman that led to multiple fetal malformations and fetal demise in Rio de Janeiro, Brazil.
Assuntos
Artrogripose/patologia , Edema/patologia , Feto/patologia , Infecções por HIV/patologia , Microcefalia/patologia , Complicações Infecciosas na Gravidez/patologia , Infecção por Zika virus/patologia , Artrogripose/diagnóstico por imagem , Artrogripose/virologia , Brasil , Edema/diagnóstico por imagem , Feminino , Morte Fetal , Feto/diagnóstico por imagem , Feto/virologia , HIV/patogenicidade , HIV/fisiologia , Infecções por HIV/diagnóstico por imagem , Infecções por HIV/virologia , Humanos , Microcefalia/diagnóstico por imagem , Microcefalia/virologia , Gravidez , Complicações Infecciosas na Gravidez/diagnóstico por imagem , Complicações Infecciosas na Gravidez/virologia , Primeiro Trimestre da Gravidez , Zika virus/patogenicidade , Zika virus/fisiologia , Infecção por Zika virus/diagnóstico por imagem , Infecção por Zika virus/virologiaRESUMO
OBJECTIVE: There are limited data regarding Xpert performance to detect Group B Streptococcus (GBS) in HIV-infected pregnant women. We evaluated the accuracy of a rapid real-time polymerase chain reaction (PCR) test in a cohort of HIV-infected women. METHODS: At 35-37 weeks of pregnancy, a pair of combined rectovaginal swabs were collected for two GBS assays in a cohort of sequentially included HIV-infected women in Rio de Janeiro: (1) culture; and (2) real-time PCR assay [GeneXpert GBS (Cepheid, Sunnyvale, CA)]. Using culture as the reference, sensitivity, specificity, positive and negative-likelihood ratios were estimated. RESULTS: From June 2012 to February 2015, 337 pregnant women met inclusion criteria. One woman was later excluded, due to failure to obtain a result in the index test; 336 were included in the analyses. The GBS colonization rate was 19.04%. Sensitivity and specificity of the GeneXpert GBS assay were 85.94% (95% CI: 75.38-92.42) and 94.85% (95% CI: 91.55-96.91), respectively. Positive and negative predictive values were 79.71% (95% CI: 68.78-87.51) and 96.63% (95% CI: 93.72-98.22), respectively. CONCLUSIONS: GeneXpert GBS is an acceptable test for the identification of GBS colonization in HIV-infected pregnant women and represents a reasonable option to detect GBS colonization in settings where culture is not feasible.
Assuntos
Complicações Infecciosas na Gravidez/diagnóstico , Reação em Cadeia da Polimerase em Tempo Real/métodos , Infecções Estreptocócicas/diagnóstico , Streptococcus agalactiae/isolamento & purificação , Adulto , Feminino , Infecções por HIV/complicações , Humanos , Transmissão Vertical de Doenças Infecciosas , Programas de Rastreamento/economia , Programas de Rastreamento/métodos , Valor Preditivo dos Testes , Gravidez , Complicações Infecciosas na Gravidez/microbiologia , Estudos Prospectivos , Infecções Estreptocócicas/complicações , Streptococcus agalactiae/genética , Fatores de Tempo , Vagina/microbiologia , Carga Viral/estatística & dados numéricos , Adulto JovemRESUMO
Our objective was to describe viral suppression and antiretroviral (ARV) resistance mutations in an ongoing cohort of perinatally-infected HIV+ (PHIV+) pregnant women. Descriptive analysis was performed using SPSS 18.0. From 2011 to 2014, we followed 22 PHIV+ pregnant women. Median age at prenatal entry was 19 years (Interquartile range (IQR) 17.6-21.0); 86% had an AIDS diagnosis; 81% had disclosed their HIV status to partner 11. The median age at HIV diagnosis was 8.3 y (IQR 4.0-13.6), the median age at sexual debut was 16 years (IQR 14-18). At the time of prenatal care initiation, four (18%) were on their first antiretroviral treatment (ART), eight (36%) in their second regimen and nine (41%) in their third regimen or beyond, and one had no data. Seventeen of 22 (77%) had HIV-viral load (VL) > 50 copies/mL at prenatal care entry, 16 had a genotyping exam performed. Seventeen of 22 PHIV+ had VL results near delivery: 7/17 (41%) had VL < 50 copies/mL. Among those who had genotyping at prenatal entry, 11/16 (69%) had mutations associated with ARV resistance. The most frequent major mutations were K103N, M184V, T215, M41L, D67N at reverse transcriptase gene and M46, I54V and V82A at protease gene. No vertical transmissions occurred. Management of pregnancy among PHIV+ is challenging. Individualized ART are needed to achieve viral suppression in a highly ART-exposed subpopulation.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Resistência à Doença/genética , Infecções por HIV/tratamento farmacológico , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Assistência Perinatal/métodos , Complicações Infecciosas na Gravidez/tratamento farmacológico , Carga Viral/efeitos dos fármacos , Adulto , Brasil , Estudos de Coortes , Feminino , Genótipo , Humanos , Recém-Nascido , Mutação , Gravidez , Complicações Infecciosas na Gravidez/virologia , Adulto JovemRESUMO
Intended and unintended pregnancies occur frequently among human immunodeficiency virus (HIV)-infected women. We evaluated the occurrence of repeat pregnancy and characteristics associated with this outcome among HIV-infected women in Latin America and the Caribbean who were participating in the National Institute of Child Health and Human Development (NICHD) International Site Development Initiative (NISDI). Of the 1342 HIV-infected pregnant women enrolled in NISDI, 124 (9.2%) had one or more repeat pregnancies on study. Median time between the index delivery and date of conception of the subsequent pregnancy was 1.4 years (range 0.1-5.7). Younger age (odds ratio [OR] = 1.07, 95% confidence interval [CI]: 1.04-1.11 per one year decrease in age), hospitalization during the index pregnancy or up to six months post-partum [OR = 2.0, 95% CI: 1.2-3.4], and poor index pregnancy outcome (stillbirth or spontaneous/therapeutic abortion; OR = 3.4, 95% CI: 1.4-8.4) were associated with increased occurrence of repeat pregnancy in multivariable analysis. Among women with repeat pregnancies, the proportion receiving antiretroviral treatment (vs. prophylaxis) increased from 39.4% at the time of the index pregnancy to 81.8% at the time of the repeat pregnancy (p < 0.001). These results can help identify women most likely to benefit from reproductive counseling in order to assist with healthy pregnancy planning and prevention of unintended pregnancies.
Assuntos
Infecções por HIV/epidemiologia , Complicações Infecciosas na Gravidez/epidemiologia , Gravidez não Planejada , Adolescente , Adulto , Região do Caribe/epidemiologia , Serviços de Planejamento Familiar , Feminino , Infecções por HIV/transmissão , Humanos , Transmissão Vertical de Doenças Infecciosas , América Latina/epidemiologia , Gravidez , Resultado da Gravidez , Adulto JovemAssuntos
Terapia Antirretroviral de Alta Atividade , Infecções por HIV/sangue , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Período Pós-Parto/sangue , Complicações Infecciosas na Gravidez/sangue , Terceiro Trimestre da Gravidez/sangue , Carga Viral , Adulto , Cesárea , Estudos de Coortes , Feminino , Infecções por HIV/tratamento farmacológico , Humanos , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológicoRESUMO
In order to understand antiretroviral resistance during pregnancy and its impact on HIV vertical transmission, we performed a cross-sectional analysis of 231 HIV-infected pregnant women who fulfilled Brazilian guidelines for antiretroviral testing and had antiretroviral genotypic testing performed between April 2010 and October 2012. At entry into prenatal care, the mean CD4 cell count for this cohort of patients was 406 cells/mm(3) (95% CI: 373-438 cells/mm(3)), while the mean HIV RNA was 24,394 copies/ml (95% CI: 18,275-30,513 copies/ml). Thirty-six women (16%) had detectable antiretroviral-resistant mutations. By 34 weeks gestation, 75% had achieved HIV RNA <400 copies/ml. Our logistic regression model showed the odds of harbouring antiretroviral-resistant virus with a baseline CD4 cell count of <200 cells/mm(3) was eight times that of subjects with CD4 cell counts >500 CD4 cells/mm(3) (95% CI 1.5-42.73). Six infants were HIV infected, four born to mothers with detectable viraemia at 34 weeks and two born to mothers who were lost to follow up. Antiretroviral resistance is common in prenatal care but did not increase vertical transmission if viral load was appropriately suppressed. Genotyping should be considered in Brazil in order to assist initiation of appropriate combination antiretroviral therapy during pregnancy to suppress viral load to avoid vertical transmission.
Assuntos
Antirretrovirais/uso terapêutico , Farmacorresistência Viral/genética , Infecções por HIV/tratamento farmacológico , HIV-1/efeitos dos fármacos , HIV-1/genética , RNA Viral/genética , Adolescente , Adulto , Terapia Antirretroviral de Alta Atividade , Brasil/epidemiologia , Contagem de Linfócito CD4 , Estudos Transversais , Feminino , Genes Virais/genética , Infecções por HIV/epidemiologia , HIV-1/isolamento & purificação , Humanos , Transmissão Vertical de Doenças Infecciosas , Modelos Logísticos , Análise Multivariada , Mutação , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Complicações Infecciosas na Gravidez/virologia , Prevalência , Carga Viral/efeitos dos fármacos , Adulto JovemRESUMO
A vaccination campaign against pandemic influenza A (H1N1)pdm09 was held in Brazil in March 2010, using two types of monovalent split virus vaccines: an AS03-adjuvanted vaccine and a non-adjuvanted vaccine. We compared the reactogenicity of the vaccines in health professionals from a Clinical Research Institute in Rio de Janeiro, Brazil and there were no serious adverse events following immunization (AEFI) among the 494 subjects evaluated. The prevalence of any AEFI was higher in the AS03-adjuvanted vaccine at 2 h and 24 h post-vaccination [preva-lence ratio (PR): 2.05, confidence interval (CI) 95%: 1.55-2.71, PR: 3.42, CI 95%: 2.62-4.48, respectively]; however, there was no difference between the vaccines in the assessments conducted at seven and 21 days post-vaccination. The group receiving the AS03 post-adjuvanted vaccine had a higher frequency of local reactions at 2 h (PR: 3.01, CI 95%: 2.12-4.29), 24 h (PR: 4.57, CI 95%: 3.29-6.37) and seven days (PR: 6.05, CI 95%: 2.98-12.28) post-vaccination. We concluded that the two types of vaccines caused no serious AEFI in the studied population and the adjuvanted vaccine was more reactogenic, particularly in the 24 h following vaccination. This behaviour must be confirmed and better characterised by longitudinal studies in the general population.
Assuntos
Adjuvantes Imunológicos/administração & dosagem , Anticorpos Antivirais/imunologia , Pessoal de Saúde , Vírus da Influenza A Subtipo H1N1/imunologia , Vacinas contra Influenza/efeitos adversos , Influenza Humana/prevenção & controle , Adulto , Brasil , Feminino , Humanos , Vacinas contra Influenza/administração & dosagem , Vacinas contra Influenza/imunologia , Influenza Humana/epidemiologia , MasculinoRESUMO
A vaccination campaign against pandemic influenza A (H1N1)pdm09 was held in Brazil in March 2010, using two types of monovalent split virus vaccines: an AS03-adjuvanted vaccine and a non-adjuvanted vaccine. We compared the reactogenicity of the vaccines in health professionals from a Clinical Research Institute in Rio de Janeiro, Brazil and there were no serious adverse events following immunization (AEFI) among the 494 subjects evaluated. The prevalence of any AEFI was higher in the AS03-adjuvanted vaccine at 2 h and 24 h post-vaccination [preva-lence ratio (PR): 2.05, confidence interval (CI) 95%: 1.55-2.71, PR: 3.42, CI 95%: 2.62-4.48, respectively]; however, there was no difference between the vaccines in the assessments conducted at seven and 21 days post-vaccination. The group receiving the AS03 post-adjuvanted vaccine had a higher frequency of local reactions at 2 h (PR: 3.01, CI 95%: 2.12-4.29), 24 h (PR: 4.57, CI 95%: 3.29-6.37) and seven days (PR: 6.05, CI 95%: 2.98-12.28) post-vaccination. We concluded that the two types of vaccines caused no serious AEFI in the studied population and the adjuvanted vaccine was more reactogenic, particularly in the 24 h following vaccination. This behaviour must be confirmed and better characterised by longitudinal studies in the general population.
Assuntos
Adulto , Feminino , Humanos , Masculino , Adjuvantes Imunológicos/administração & dosagem , Anticorpos Antivirais/imunologia , Pessoal de Saúde , Vírus da Influenza A Subtipo H1N1/imunologia , Vacinas contra Influenza/efeitos adversos , Influenza Humana/prevenção & controle , Brasil , Vacinas contra Influenza/administração & dosagem , Vacinas contra Influenza/imunologia , Influenza Humana/epidemiologiaRESUMO
Group B Streptococcus (GBS) is a leading cause of infectious morbidity in newborns. We describe the prevalence of GBS colonization and the serotypes and antibiotic susceptibility profiles of isolates obtained from a cohort of human immunodeficiency virus (HIV)-infected pregnant women. This was a cross-sectional study at a centre for the prevention of mother-to-child transmission of HIV. Vaginal and rectal swabs were collected at 35-37 weeks of gestation from 158 eligible women. GBS isolates were serotyped and antimicrobial susceptibility tests performed. Patient sociodemographic characteristics, CD4 counts and viral loads were abstracted from records. The overall anogenital prevalence of GBS colonization was 49/158 (31.0%): 40/158 (25.3%) for vagina, 19/158 (12.0%) for rectum and 10/158 (6.3%) for both. Predominant serotypes were Ib (34.9%) and Ia (25.6%). All were penicillin-susceptible. Two were resistant to erythromycin (4.0%) and one to clindamycin (2.0%). The colonization rate by GBS was high in this cohort. Serotype Ib was the most frequently identified.